CLASS II ONGOING Drug recall · Reported 2 Mar 2022 · FDA Enforcement Report

Methylphenidate Hydrochloride Chewable Tablets, 2.5 mg recalled

Rising Pharmaceuticals is recalling Methylphenidate Hydrochloride Chewable Tablets, 2.5 mg, distributed nationwide in the US. The recall was initiated on 7 Feb 2022 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codeslot# 25910009, Exp 01/2023
NDC64980-221, 64980-222, 64980-223
Quantity recalled2220 100-count bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0573-2022
FDA event ID
89545
Recalling firm
Rising Pharmaceuticals, East Brunswick, NJ
Manufacturer
Rising Pharma Holdings, Inc.
Classification
Class II
Status
Ongoing
Recall initiated
7 Feb 2022
FDA classified
22 Feb 2022
Reported
2 Mar 2022
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Packaging Defects
Drug class
ADHD Medication

Timeline

7 Feb 2022Recall initiated by company
22 Feb 2022Classified by FDA+15 days
2 Mar 2022Published in enforcement report+8 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Failed Tablet Specifications: Recall of this drug product was voluntarily initiated by the manufacturer due to a market complaint, which stated that a tablet in the sealed bottle was twice larger in size when compared to the remaining tablets. This complaint is second of its kind.

Packaging recalls include wrong labels, wrong products in the wrong bottle, missing leaflets, short-filled or empty capsules and seals that fail.

Product as listed by the FDA

Methylphenidate Hydrochloride Chewable Tablets, 2.5 mg, 100-count bottle, Rx Only, Manufactured for: Rising Pharmaceuticals Inc., Saddle Brook, NJ 07863, NDC 64980-221-01

Where it was distributed

Nationwide in the USA

Nationwide

Questions about this recall

Why was it recalled?

Failed Tablet Specifications: Recall of this drug product was voluntarily initiated by the manufacturer due to a market complaint, which stated that a tablet in the sealed bottle was twice larger in size when compared to the remaining tablets. This complaint is second of its kind.

Which lots are affected?

lot# 25910009, Exp 01/2023

Where was it sold?

Nationwide in the USA

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Rising Pharmaceuticals

All 9

Other Methylphenidate recalls

All 54